部份中文盐酸奥洛他定处方资料（仅供参考）
通用名称：盐酸奥洛他定滴眼液
英文名称：Olopatadine Hydrochloride
商标名称：Patanol Ophthalmic Solution 0.1％
适应症：
用于治疗过敏性结膜炎的体征和症状。
用法用量：
推荐剂量为患眼每次1-2滴，每日2次，间隔6-8小时以上。
不良反应：
已有报告，用药后头痛的发生率为7%。下列不良反应已有报告，发生率小于5% ：乏力，视力模糊，烧灼或刺痛感，感冒综合征，眼干，异物感，充血，过敏，角膜炎，眼睑水肿，恶心，咽炎，瘙痒，鼻炎，鼻窦炎及味觉倒错。相当一部分的不良反应和疾病本身的症状相似。
禁忌症：
对任何成份过敏者禁用。
日本协和发酵公司研发。日本爱尔康(Alcon)公司从协和公司引入并将其开发成0.1%滴眼液。上市情况：Allelock于2001年3月在日本上市。Patanol（眼药水）1996年12月获FDA批准，已在30多个国家上市。
日本上市资料附件：http://www.info.pmda.go.jp/go/pack/1319752Q1024_2_01/
Purpose: To compare the clinical efficacy of Patanol® (olopatadine hydrochloride ophthalmic solution 0.1%) to Claritin® (loratadine 10 mg) tablets, in the conjunctival allergen challenge model.
Methods: This was a randomized, double‐masked, single center, contralateral controlled, antigen challenge model study. The concentration of allergen that elicited a positive response was determined at Visits 1 and 2 (itching ≥2 and redness ≥2 OU). At Visit 3, 29 subjects were randomized into two groups. Fifteen subjects received Claritin® tablet and Patanol® ophthalmic solution 0.1% in one eye and placebo in the contralateral eye. Fourteen subjects received placebo tablet and Patanol® in one eye and placebo in the contralateral eye. One hour after drug administration, subjects were challenged with the antigen that elicited a positive response. At 3, 7, and 10 minutes, itching was subjectively eva luated. At Visit 4, the same procedure was followed as in Visit 3, but antigen challenge occurred 8 hours after drug instillation.
Results: Results were analyzed by eye. Eyes treated with Patanol® (concomitant with placebo tablet) had significantly lower ocular itching scores when compared to eyes treated with placebo (concomitant with Claritin®) at 3, 7 and 10 minutes in the onset of action eva luation (p<0.05). Eyes treated with Patanol® (concomitant with placebo tablet) had significantly lower ocular itching scores at 7 minutes and there was a statistical trend (0.05<p<0.1) at 10 minutes in duration of action eva luation.
Conclusions: Patanol® therapy was significantly more efficacious than Claritin® in reducing ocular itching related to allergic conjunctivitis.